FDA grants EUA to BD s SARS-CoV-2/Flu assay
FDA grants EUA to BD s SARS-CoV-2/Flu assay
15 February 2021 | News The BD® SARS-CoV-2/Flu assay is run on the BD MAX™ System and distinguishes between SARS-CoV-2 and Influenza A+B, providing a positive or negative result for each virus using a single specimen
Source: PR Newswire
BD (Becton, Dickinson and Company), a leading global medical technology company, has announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and Influenza A+B that can return results in two to three hours. The new test also has been CE marked to the IVD Directive (98/79/EC).